Belite Bio (BLTE) to offer ADS and warrants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants
May 30, 2023 4:01 PM EDTSAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (Belite Bio or the Company), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced that it has commenced an underwritten public offering of American Depositary Shares (ADSs), each representing one of its ordinary shares, and warrants to purchase ordinary shares represented by ADSs. All of the securities in the offering are to be sold by Belite Bio. The offering is subject to market... More
